TCT-750 Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Abstract

In the HORIZONS-AMI (HZN) trial, among STEMI patients undergoing primary PCI after aspirin and clopidogrel loading, anticoagulation with bivalirudin (BIV) (in most patients terminated at end of the PCI procedure)reduced major bleeding, thrombocytopenia and mortality compared to unfractionated